ANTLERON
Your Advanced Therapy Partner
Turn cells into personalized therapies
Hybrid R&D Approach
Biopharmaceutical manufacturing has evolved from large-scale, manual operations to automated and personalized micro-production. At Antleron, we pioneer a novel hybrid R&D approach: a living, digitalized ecosystem where cells become the factory, producing personalized medicines in a closed, automated, and intelligently monitored environment.
Gene Therapy Innovation
Antleron’s unique technology is based on hybrid cell culture process development. We integrate a scalable, closed and automated upstream bioreactor platform CellGuide® with a digital model counterpart (twin), called NEXUS. This enables our customers to deliver cell and gene therapies to patients in a faster, more affordable, and more equitable way. Read here about some successful collaborations.
Smart Scaled-Down Model
From discovery to process development, Antleron’s smart scaled-down model service combines custom, lab-scale, modular bioreactors with its Nexus-driven digital twin platform to predict, develop and optimize clinical-scale bioprocesses and manufacturing systems. Antleron’s CellGuide® fixed-bed upstream bioreactor platform completes its smart scaled-down model offering by enabling improved quality, consistency and scalability from lab to patient for bespoke therapies.
Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) have the ability to secrete bioactive factors, modulate immune responses, and differentiate into multiple lineages which makes them highly versatile for treating inflammatory, degenerative, and autoimmune conditions. ​
​
Antleron addresses these challenges by engineering robust MSC bioprocesses that preserve critical quality attributes (CQAs) from lab to clinic.
rAAV vectors
Recombinant adeno-associated viral vectors are the backbone of many gene therapy platforms due to their safety, tissue specificity, and long-term expression. Human Embryonic Kidney (HEK) cells are widely used for rAAV production. ​
​
Antleron has developed a fixed-bed bioreactor technology, tailored for adherent HEK cell culture, enabling robust, scalable, and GMP-aligned rAAV production.
Extracellular Vesicles
Mesenchymal stem cells (MSCs) exert powerful effects through their secretome that modulate immune responses, promote tissue repair, and influence regeneration. These cell-free products are emerging as next-generation biologics.
Antleron has designed an essential adherent culture in a controlled environment that preserves the therapeutic integrity of secreted products.
Follow Us On LinkedIn
For the latest news about Antleron, visit our LinkedIn page, or find out more in our News page!
